Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| HWK-016 (MUC16 Targeted ADC) | Ovarian And Endometrial Cancers | Phase 1 | Jun 30, 2027 | Mgmt interest |
| HWK-007 | NSCLC, ovarian, endometrial cancers | Phase 1 | Jun 30, 2027 | Mgmt interest |
Upcoming milestones
Company profile
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Ovarian And Endometrial Cancers
Data readoutNSCLC, ovarian, endometrial cancers
Data readout